25E-NBOH (2C-E-NBOH, NBOH-2C-E) is a derivative of the phenethylamine derived hallucinogen 2C-E. It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent,[2] but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper,[3][4][5] as well as in Slovenia.[6] It acts as a potent serotonin receptor agonist with similar affinity to better-known compounds such as 25I-NBOMe at 5-HT2A and 5-HT2C receptors.[7]
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
UNII |
|
Chemical and physical data | |
Formula | C19H25NO3 |
Molar mass | 315.413 g·mol−1 |
3D model (JSmol) |
|
| |
|
This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[8]